trastuzumab,capecitabine,zolbetuximab,epirubicin,oxaliplatin
roche,astellas
[]
dr. wang on spotlight, 1st mol subset showing benefit since trastuzumab in adv #gastric/gej cancer exclusive of ios - validates as a new biomarker but notably cldn18.2 subset a better prognostic subset in this pop given over-performing control arm to historical? #gi23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope